P

Inventor

KIM JOSEPH L

US64 patents
⚠️ This page may combine multiple inventors who share the name “KIM JOSEPH L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BLUEPRINT MEDICINES CORP

25 patents
US9944651B2Apr 17, 2018

Compositions useful for treating disorders related to kit

BLUEPRINT MEDICINES CORP33 citations98
US9340514B2May 17, 2016

Inhibitors of the fibroblast growth factor receptor

BLUEPRINT MEDICINES CORP43 citations97
US10584114B2Mar 10, 2020

Inhibitors of RET

BLUEPRINT MEDICINES CORP13 citations94
US10202365B2Feb 12, 2019

2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

BLUEPRINT MEDICINES CORP20 citations94
US10030005B2Jul 24, 2018

Inhibitors of RET

BLUEPRINT MEDICINES CORP38 citations94
US9994575B2Jun 12, 2018

Compositions useful for treating disorders related to kit

BLUEPRINT MEDICINES CORP32 citations94
US9994552B2Jun 12, 2018

Compositions useful for treating disorders related to kit

BLUEPRINT MEDICINES CORP31 citations94
US9884861B2Feb 6, 2018

Compositions useful for treating disorders related to kit

BLUEPRINT MEDICINES CORP32 citations94
US10233186B2Mar 19, 2019

Inhibitors of activin receptor-like kinase

BLUEPRINT MEDICINES CORP16 citations93
US11279688B2Mar 22, 2022

Inhibitors of RET

BLUEPRINT MEDICINES CORP5 citations84
US10774070B2Sep 15, 2020

2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors

BLUEPRINT MEDICINES CORP6 citations84
US10183928B2Jan 22, 2019

Inhibitors of RET

BLUEPRINT MEDICINES CORP13 citations84
US10378063B2Aug 13, 2019

RAF1 fusions

BLUEPRINT MEDICINES CORP8 citations82
US11827642B2Nov 28, 2023

Compositions useful for treating disorders related to KIT

BLUEPRINT MEDICINES CORP2 citations73
US11534441B2Dec 27, 2022

MAP4K1 inhibitors

BLUEPRINT MEDICINES CORP3 citations72
US11970498B2Apr 30, 2024

CDK2 inhibitors

BLUEPRINT MEDICINES CORP1 citations71
US11718602B2Aug 8, 2023

EGFR inhibitors

BLUEPRINT MEDICINES CORP2 citations70
US11634422B2Apr 25, 2023

Inhibitors of activin receptor-like kinase

BLUEPRINT MEDICINES CORP1 citations70
US11236086B2Feb 1, 2022

Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase

BLUEPRINT MEDICINES CORP1 citations62
US11040979B2Jun 22, 2021

Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR

BLUEPRINT MEDICINES CORP0 citations62
US10370379B2Aug 6, 2019

Compounds and compositions useful for treating disorders related to NTRK

BLUEPRINT MEDICINES CORP1 citations62
US12545684B2Feb 10, 2026

CDK2 inhibitors

BLUEPRINT MEDICINES CORP0 citations61
US12042495B2Jul 23, 2024

MAP4K1 inhibitors

BLUEPRINT MEDICINES CORP1 citations61
US11932648B2Mar 19, 2024

CDK2 inhibitors

BLUEPRINT MEDICINES CORP1 citations61
US11261497B2Mar 1, 2022

PRKC fusions

BLUEPRINT MEDICINES CORP0 citations61

AMGEN INC

13 patents

VERTEX PHARMA

5 patents

HODOUS BRIAN L

2 patents

BIFULCO JR NEIL

2 patents

DIPIETRO LUCIAN V

1 patent

GEUNS-MEYER STEPHANIE D

1 patent

CHEN GUOQING

1 patent

Showing the top 50 of 64 patents by PatentIndex Score.